Atjaunināt sīkdatņu piekrišanu

G Protein-Coupled Receptors as Drug Targets: Analysis of Activation and Constitutive Activity [Hardback]

Series edited by (University of Heidelberg, Germany), Edited by (University of Regensburg, Germany), Series edited by (University of Düsseldorf, Germany), Series edited by (ETH Zürich, Switzerland), Edited by (University of Heidelberg, Germany)
  • Formāts: Hardback, 304 pages, height x width x depth: 246x175x20 mm, weight: 694 g
  • Sērija : Methods & Principles in Medicinal Chemistry
  • Izdošanas datums: 01-Nov-2005
  • Izdevniecība: Blackwell Verlag GmbH
  • ISBN-10: 3527308199
  • ISBN-13: 9783527308194
Citas grāmatas par šo tēmu:
  • Hardback
  • Cena: 253,65 €*
  • * Šī grāmata vairs netiek publicēta. Jums tiks paziņota lietotas grāmatas cena
  • Šī grāmata vairs netiek publicēta. Jums tiks paziņota lietotas grāmatas cena.
  • Daudzums:
  • Ielikt grozā
  • Pievienot vēlmju sarakstam
  • Bibliotēkām
G Protein-Coupled Receptors as Drug Targets: Analysis of Activation and Constitutive ActivityPalielināt
  • Formāts: Hardback, 304 pages, height x width x depth: 246x175x20 mm, weight: 694 g
  • Sērija : Methods & Principles in Medicinal Chemistry
  • Izdošanas datums: 01-Nov-2005
  • Izdevniecība: Blackwell Verlag GmbH
  • ISBN-10: 3527308199
  • ISBN-13: 9783527308194
Citas grāmatas par šo tēmu:
Permanent link: https://www.kriso.lv/db/9783527308194.html
Keywords:
With its particular emphasis on the constitutive activity of G-protein-coupled receptors (GPCRs)s, this book comprehensively discusses an important biological process that has not yet been covered in such depth in any other existing books on GPCRs. The international team of highly distinguished authors addresses in detail current models and concepts, to introduce medicinal chemists, physiologists, pharmacologists, and medical researchers into the advances in the understanding of GPCR activation and constitutive activity. In addition, the book provides an overview on methods of investigating constitutive GPCR activity. The text is well illustrated by selected experimental data and schemes._The chaptes are all cross-referenced with each other and cover general mechnisms, methodological approaches and cover selected important GPCR sysstems, the consequences for drug action, including, side effects, and rational drug design for GPCR targets. A highly recommended reference for researchers in academia and industry.

authors addresses in detail current models and concepts, so as to introduce pharmaceutical chemists, physiologists and medical researchers to the advances in the understanding of GPCR activation and constitutive activity, and provides an overview of the methods of investigating GPCR activity. The text is backed by abundant case studies and methodological advice for analyzing GPCRs, covering selected pharmacologically relevant GPCR systems, the consequences for drug action, including unwanted side effects, and rational drug design for GPCR targets.
A highly practical reference for researchers in academia and industry.

Recenzijas

"In conclusion, this volume can be highly useful resource for pharmaceuticals chemists, physiologists and medical researchers working both in academia and industry." International Journal of Biological Macromolecules

"...extremely informative and generally easy to read and understand. It is an important reference book for researchers (medicinal chemists, physiologists, and pharmacologists) working on the most favorite group of drug targets - the GPCRs." ChemMedChem

"This book is an excellent review of the body of evidence describing constitutive GPCR activity. It is of general interest to pharmacologists, structural biologists, biochemists, and medicinal chemists with an interest in GPCR signaling pathways and as such would be a good addition to personal or departmental libraries of many basic scientists." Journal of Medicinal Chemistry

"I can strongly recommend this book as the concepts and examples have mostly been poorly taken into account with the daily work in the laboratory. The book would have great use in pharmacologically oriented laboratories in academics as well as different stages in drug development in pharmaceutical industry. It is more or less a "must" in the libraries in academia and in industry looking on all kinds of GPCR research." Arch. Pharm. Chem. Life Sci. "Anders als bei anderen vergleichsweisen Buchveröffentlichungen hat man hier immer das Gefühl der Homogenität und Harmonie der Darstellungen der verschiedenen Autoren in den verschiedenen Kapiteln. Gute und ausführliche Quellenhinweise, einwandfreie Abbildungen und Darstellungen sowie das hilfreiche Abkürzungsglossar zu Anfang machen dieses Buch zu einer Pflichtlektüre für Zellbiologen, Pharmakologen und fachinteressierte Studierende." Umwelt & Gesundheit

Preface.
A Personal Foreword.
List of Contributors.
Abbreviations and Terminology.
I: General Concepts.
1. Historical Background and Introduction.
2. The Nature of Constitutive Activity and Inverse Agonism.
2.1 Historical Perspective.
2.2 Theoretical Basis of Inverse Agonism: Relevance of Receptor Type.
2.3 The Interaction of Systems with Ligands.
2.4 Inverse Agonism as a Phenotypic Behavior.
2.5 Conclusion.
3. Molecular Mechanisms of GPCR Activation.
3.1 Introduction.
3.2 GPCR Structure and Ligand Recognition.
3.3 Conformational Changes in the GPCR Activation Process.
3.4 Conversion to the Active Receptor State Involves Release of Stabilizing Intramolecular Interactions.
3.5 Kinetics of Agonist Binding and Receptor Activation.
3.6 GPCR Activation in an Oligomeric Context.
4. Molecular and Cellular Determinants of GPCR Splice Variant Constitutive Activity.
4.1 Introduction.
4.2 Constitutive Activation of Second Messenger Production by C-Terminal Splice Variants of GPCRs.
4.3 Differential Constitutive Internalization of C-t GPCR Splice Variants.
4.4 Conclusion.
5. Naturally Occurring Constitutively Active Receptors: Physiological and Pharmacological Implications.
5.1 Introduction.
5.2 Wild-type Interspecies Homologues.
5.3 Wild-type Receptor Subtypes within a Given Species.
5.4 Wild-type Alternatively Spliced Receptors.
5.5 Polymorphisms in GPCRs.
5.6 GPCR Mutation-induced Disease.
5.7 Future Challenges.
6. The Impact of G Proteins on Constitutive GPCR Activity.
6.1 Introduction.
6.2 The Contribution of G proteins to Constitutive Activity.
6.3 GPCR–G Protein Fusion Proteins.
6.4 Conclusions.
7. (Patho)physiological and Therapeutic Relevance of Constitutive Activity and Inverse Agonism at G Protein-Coupled Receptors.
7.1 Introduction.
7.2 Physiological Relevance of Constitutive Activity of GPCRs.
7.3 Constitutive Activity of GPCRs and Pathophysiology of Disease.
7.4 Physiological Relevance of Inverse Agonists.
7.5 Inverse Agonists as Drugs.
7.6 Conclusions.
8. Methodological Approaches.
8.1 Introduction.
8.2 Analysis of Constitutive GPCR Activity in Membranes and Intact Cells.
8.3 Measurement of Constitutive Activity of GPCRs in Intact Cells.
II: Constitutive Activity of Selected GPCR Systems.
9. Constitutive Activity of b-Adrenoceptors: Analysis in Membrane Systems.
9.1 Introduction.
9.2 Analysis of βAR/Gs Protein Coupling in Membranes.
9.3 Development of the Concept that βARs are Constitutively Active.
9.4 Probing Models of GPCR Activation with β2ARwt and β2ARCAM with Inverse Agonists.
9.5 Probing Models of GPCR Activation with β2ARwt and β2ARCAM and with Partial and Full Agonists.
9.6 Probing Models of GPCR Activation with β2ARwt and Purine Nucleotides.
9.7 Constitutive Activity of the β2AR Coupled to Various GΑs Proteins.
9.8 Probing Models of GPCR Activation with β2AR Coupled to Various Classes of G proteins.
9.9 Comparison of the Constitutive Activities of the β1AR and the β2AR.
9.10 Conclusions.
10. Constitutive Activity of Β-Adrenoceptors: Analysis by Physiological Methods.
10.1 Introduction.
10.2 Constitutive Activity and Inverse Agonism: Definition and Detection.
10.3 β1-Adrenoceptors.
10.4 β2-Adrenoceptors.
10.5 Homo- and Heterodimerization of β1- and β2ARs.
10.6 Conclusions.
11. Constitutive Activity at the α1-Adrenoceptors: Past and Future Implications.
11.1 Introduction.
11.2 Theoretical and Experimental Approaches for Study of Constitutive GPCR Activity.
11.3 Constitutively Activating Mutations of the α1AR Subtypes.
11.4 A Putative Model of Receptor Activation for the α1BAR.
11.5 Constitutive Activity of Wild-type α1ARs and Inverse Agonism.
11.6 Receptor Regulation and Constitutive Activity of the α1ARs.
11.7 Conclusions.
12. Constitutive Activity of Muscarinic Acetylcholine Receptors: Implications for Receptor Activation and Physiological Relevance.
12.1 Introduction.
12.2 Constitutive Activity – Native Systems.
12.3 Constitutive Activity – Recombinant Systems.
12.4 Constitutive Activation by G Proteins.
12.5 Structure–Function Analysis of Receptor Activation.
12.6 Structure–Function Model for Activation.
12.7 Conclusions.
13. Constitutively Active Histamine Receptors.
13.1 Introduction.
13.2 The Histamine Receptors.
13.3 Assay Systems for Detection of Constitutive Activity of Histamine Receptors.
13.4 Conclusions.
14. Constitutively Active Serotonin Receptors.
14.1 Introduction.
14.2 5-HT1A Receptor (5-HT1AR).
14.3 5-HT1B and 5-HT1D Receptors (5-HT1BR and 5-HT1DR).
14.4 5-HT2A Receptor (5-HT2AR).
14.5 5-HT2C Receptor (5-HT2CR).
14.6 Conclusion.
15. Virally Encoded Constitutively Active Chemokine Receptors.
15.1 Introduction.
15.2 The Human Cytomegalovirus-encoded Chemokine Receptor Homologue pUS28.
15.3 The Human Kaposi’s Sarcoma Virus-encoded Chemokine Receptor KSHV-GPCR.
15.4 Conclusions.
Index.


Roland Seifert was born in 1960 in Berlin, Germany. He was fellow of the Merit Scholar Foundation of Germany and earned his MD degree at the Free University of Berlin in 1986. From 1986-1995 he worked in the group of Professor Gunter Schultz in the Department of Pharmacology of the Free University of Berlin. From 1995-1998, he worked with Dr. Brian Kobilka at Stanford University, CA, USA. From 1998-2004 he was Associate Professor in the Department of Pharmacology and Toxicology of The University of Kansas, Lawrence, KS, USA before taking over the Chair of Pharmacology and Toxicology at The University of Regensburg, Germany. His research focuses on the molecular mechanisms of GPCR-activation, G-protein function and adenylyl cyclase regulation.

Thomas Wieland was born in 1960 in Karlsruhe, Germany. He studied Pharmacy at the University of Heidelberg where he obtained his PhD in Pharmacology in 1989. From 1990-1996 he worked in the group of Professor Karl H. Jakobs in the Department of Pharmacology of the Universities of Heidelberg and Essen, Germany. From 1996 -1997, he was a research fellow with Dr. Melvin I. Simon at the California Institute of Technology, Pasadena, CA, USA. From 1997 - 2002 he was Professor in the Department of Pharmacology and Toxicology of the University of Hamburg, Germany. Since July 2002 he is Professor of Pharmacology and Toxicology at the University of Heidelberg, Germany. His research focuses on the GPCR induced activation of heterotrimeric G-proteins and monomeric GTPases and the regulation of these processes by accessory proteins.